We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Roche NimbleGen and Sigma-Aldrich Collaborate to Advance Epigenetic Research
News

Roche NimbleGen and Sigma-Aldrich Collaborate to Advance Epigenetic Research

Roche NimbleGen and Sigma-Aldrich Collaborate to Advance Epigenetic Research
News

Roche NimbleGen and Sigma-Aldrich Collaborate to Advance Epigenetic Research

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche NimbleGen and Sigma-Aldrich Collaborate to Advance Epigenetic Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roche NimbleGen and Sigma-Aldrich have started a collaboration to further chromatin immunoprecipitation on microarray (ChIP-chip) research by aligning their two complementary technologies, Roche NimbleGen’s ChIP-chip high-density microarrays and GenomePlex™ by Sigma-Aldrich.

Together, the platforms enable researchers to effectively study the entire genome for epigenetic interactions between DNA and DNA-binding proteins to determine regions of the genome that are transcriptionally active or repressed and the mechanisms that regulate these processes.

Understanding the fundamental epigenomic and genomic regulatory pathways underlying normal cell growth and tissue differentiation, as well as changes in regulatory control associated with disease, is crucial for the development of drugs that target these pathways.

To facilitate the ChIP-chip workflow, Roche NimbleGen and Sigma-Aldrich will publish protocols for ChIP-chip research and provide technical support to researchers integrating the two technologies, as well as co-market their complementary products.

ChIP-chip combines chromatin immunoprecipitation (ChIP) with microarrays to understand DNA-protein interactions. The ChIP step deploys a specific antibody against a regulatory protein of interest, which results in the enrichment of DNA fragments bound to the target protein. Usually these enriched DNA fractions are at very low concentrations and need to be further amplified for detection.

The technologies from Sigma-Aldrich and Roche NimbleGen facilitate ChIP-chip research by addressing two critical bottlenecks in the workflow: efficient amplification of targeted sections of DNA and high-resolution microarray detection.

For researchers, GenomePlex is the preferred method for amplifying targeted small (less than 200bp) DNA fragments in an efficient and unbiased manner. The amplified genome can then be analyzed on Roche NimbleGen’s high density (up to 2.1 million probes per array), long oligonucleotide, ChIP-chip arrays to examine the interactions between DNA and proteins such as transcription factors, histones and polymerases.
Advertisement